In recent years, monoclonal antibodies targeting TNF-alpha, such as infliximab, have been widely used to treat Crohn’s disease, demonstrating effectiveness in reducing inflammation (Belaiche and Louis, 2000). This evidence concerns the gene TNF and Crohn disease.